Literature DB >> 10364381

Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6.

K Kawana1, H Yoshikawa, Y Taketani, K Yoshiike, T Kanda.   

Abstract

Studies of virus neutralization by antibody are a prerequisite for development of a prophylactic vaccine strategy against human papillomaviruses (HPVs). Using HPV16 and -6 pseudovirions capable of inducing beta-galactosidase in infected monkey COS-1 cells, we examined the neutralizing activity of mouse monoclonal antibodies (MAbs) that recognize surface epitopes in HPV16 minor capsid protein L2. Two MAbs binding to a synthetic peptide with the HPV16 L2 sequence of amino acids (aa) 108 to 120 were found to inhibit pseudoinfections with HPV16 as well as HPV6. Antisera raised by immunizing BALB/c mice with the synthetic peptide had a cross-neutralizing activity similar to that of the MAb. The data indicate that HPV16 and -6 have a common cross-neutralization epitope (located within aa 108 to 120 of L2 in HPV16), suggesting that this epitope may be shared by other genital HPVs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364381      PMCID: PMC112690     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  13 in total

1.  Generation and neutralization of pseudovirions of human papillomavirus type 33.

Authors:  F Unckell; R E Streeck; M Sapp
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

2.  Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions.

Authors:  W J Liu; L Gissmann; X Y Sun; A Kanjanahaluethai; M Müller; J Doorbar; J Zhou
Journal:  Virology       Date:  1997-01-20       Impact factor: 3.616

Review 3.  Papillomavirus infections--a major cause of human cancers.

Authors:  H zur Hausen
Journal:  Biochim Biophys Acta       Date:  1996-10-09

4.  Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies.

Authors:  J M Gaukroger; L M Chandrachud; B W O'Neil; G J Grindlay; G Knowles; M S Campo
Journal:  J Gen Virol       Date:  1996-07       Impact factor: 3.891

5.  In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.

Authors:  R B Roden; H L Greenstone; R Kirnbauer; F P Booy; J Jessie; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

6.  Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4.

Authors:  L M Chandrachud; G J Grindlay; G M McGarvie; B W O'Neil; E R Wagner; W F Jarrett; M S Campo
Journal:  Virology       Date:  1995-08-01       Impact factor: 3.616

7.  In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids.

Authors:  K Kawana; H Yoshikawa; Y Taketani; K Yoshiike; T Kanda
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

8.  A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2.

Authors:  K Kawana; K Matsumoto; H Yoshikawa; Y Taketani; T Kawana; K Yoshiike; T Kanda
Journal:  Virology       Date:  1998-06-05       Impact factor: 3.616

9.  Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.

Authors:  R B Roden; E M Weissinger; D W Henderson; F Booy; R Kirnbauer; J F Mushinski; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

10.  Antibodies to human papillomavirus 16, 18, 58, and 6b major capsid proteins among Japanese females.

Authors:  K Matsumoto; H Yoshikawa; Y Taketani; K Yoshiike; T Kanda
Journal:  Jpn J Cancer Res       Date:  1997-04
View more
  55 in total

1.  DNA-induced structural changes in the papillomavirus capsid.

Authors:  C Fligge; F Schäfer; H C Selinka; C Sapp; M Sapp
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 2.  Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications.

Authors:  Allison H Bartlett; Pyong Woo Park
Journal:  Expert Rev Mol Med       Date:  2010-02-01       Impact factor: 5.600

3.  The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle.

Authors:  Sigrid C Holmgren; Nicole A Patterson; Michelle A Ozbun; Paul F Lambert
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 4.  Virus-like particles production in green plants.

Authors:  Luca Santi; Zhong Huang; Hugh Mason
Journal:  Methods       Date:  2006-09       Impact factor: 3.608

5.  Prophylactic immunization with human papillomavirus vaccines induces oral immunity in mice.

Authors:  Julie Ahn; Shiwen Peng; Chien-Fu Hung; Richard B S Roden; Simon R Best
Journal:  Laryngoscope       Date:  2017-09-04       Impact factor: 3.325

6.  Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

Authors:  Ratish Gambhira; Subhashini Jagu; Balasubramanyam Karanam; Patti E Gravitt; Timothy D Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

7.  Bovine papillomavirus type 1 infection is mediated by SNARE syntaxin 18.

Authors:  Valerie Laniosz; Kha C Nguyen; Patricio I Meneses
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

8.  Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.

Authors:  Andrew G Diamos; Dalia Larios; Lauren Brown; Jacquelyn Kilbourne; Hyun Soon Kim; Divyasha Saxena; Kenneth E Palmer; Hugh S Mason
Journal:  Vaccine       Date:  2018-11-17       Impact factor: 3.641

9.  Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.

Authors:  Subhashini Jagu; Kihyuck Kwak; John T Schiller; Douglas R Lowy; Harold Kleanthous; Kirill Kalnin; Chenguang Wang; Hsu-Kun Wang; Louise T Chow; Warner K Huh; Kilvani S Jaganathan; Sudha V Chivukula; Richard B S Roden
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

10.  Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.

Authors:  Monica E Embers; Lynn R Budgeon; Martin Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.